nach oben

Head and Neck Pathology

Erschienen in:

31.08.2019 | Original Paper

The Significance of Relative Claudin Expression in Odontogenic Tumors

verfasst von: Ekarat Phattarataratip, Kraisorn Sappayatosok

Erschienen in: Head and Neck Pathology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Claudins are integral to the structure and function of tight junctions. Altered claudin expression has been shown to affect disease behavior and patient prognosis in various neoplasms. The objectives of this study were to analyze the claudin-1, -4 and -7 expression in odontogenic tumors and characterize their expression pattern in distinct tumor cell types in relation to the recurrence potential. Sixty-nine cases of odontogenic tumors, including 43 ameloblastomas (AM), 17 adenomatoid odontogenic tumors (AOT), 6 ameloblastic fibromas (AF) and 3 ameloblastic carcinomas (AC) were investigated for claudin-1, -4 and -7 expression immunohistochemically. The staining was analyzed semi-quantitatively and categorized into 4 levels, based on the percentage of positively stained neoplastic epithelial cells. Claudin-1 was expressed in all AOT and AF cases, whereas most AC (66.7%) showed no expression. The claudin-1 staining was moderate-to-intense in the odontogenic epithelium of AF. In contrast, its staining of ameloblast-like cells and stellate reticulum-like cells in AM was weak. Claudin-7 expression was noted in all tumor types studied, while the expression of claudin-4 was limited and mainly localized in the squamous differentiated cells of AM and AC. AM showed significantly higher claudin-4, but lower claudin-7 expression than AOT. In addition, AC showed diminished claudin-1 immunoreactivity, compared to AOT. Low claudin-1 expression in AM was significantly associated with the increased clinical recurrence. The loss of claudin-1 may underlie the locally invasive nature of AM.

Singh AB, Uppada SB, Dhawan P. Claudin proteins, outside-in signaling, and carcinogenesis. Pflug Arch. 2017;469(1):69–75. https://doi.org/10.1007/s00424-016-1919-1.CrossRef

Severson EA, Parkos CA. Mechanisms of outside-in signaling at the tight junction by junctional adhesion molecule A. Ann N Y Acad Sci. 2009;1165:10–8. https://doi.org/10.1111/j.1749-6632.2009.04034.x.CrossRefPubMed

Tsukita S, Tanaka H, Tamura A. The Claudins: from tight junctions to biological systems. Trends Biochem Sci. 2019;44(2):141–52. https://doi.org/10.1016/j.tibs.2018.09.008.CrossRefPubMed

Pope JL, Bhat AA, Sharma A, Ahmad R, Krishnan M, Washington MK, et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut. 2014;63(4):622–34. https://doi.org/10.1136/gutjnl-2012-304241.CrossRefPubMed

Kwon MJ. Emerging roles of claudins in human cancer. Int J Mol Sci. 2013;14(9):18148–80. https://doi.org/10.3390/ijms140918148.CrossRefPubMedPubMedCentral

Singh AB, Dhawan P. Claudins and cancer: fall of the soldiers entrusted to protect the gate and keep the barrier intact. Semin Cell Dev Biol. 2015;42:58–65. https://doi.org/10.1016/j.semcdb.2015.05.001.CrossRefPubMed

Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 2007;20(2):139–43.PubMed

Sauer T, Pedersen MK, Ebeltoft K, Naess O. Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology. 2005;16(4):193–8. https://doi.org/10.1111/j.1365-2303.2005.00257.x.CrossRefPubMed

Miyamoto K, Kusumi T, Sato F, Kawasaki H, Shibata S, Ohashi M, et al. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed Res. 2008;29(2):71–6.CrossRef

10.

Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, et al. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol. 2006;37(5):569–77. https://doi.org/10.1016/j.humpath.2005.12.018.CrossRefPubMed

11.

Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007;38(4):564–9. https://doi.org/10.1016/j.humpath.2006.11.007.CrossRefPubMed

12.

Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005;115(7):1765–76. https://doi.org/10.1172/JCI24543.CrossRefPubMedPubMedCentral

13.

Sappayatosok K, Phattarataratip E. Overexpression of claudin-1 is associated with advanced clinical stage and invasive pathologic characteristics of oral squamous cell carcinoma. Head Neck Pathol. 2015;9(2):173–80. https://doi.org/10.1007/s12105-014-0559-z.CrossRefPubMed

14.

Zhang WN, Li W, Wang XL, Hu Z, Zhu D, Ding WC, et al. CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis. Oncotarget. 2016;7(52):87449–61. https://doi.org/10.18632/oncotarget.13871.CrossRefPubMedPubMedCentral

15.

Konecny GE, Agarwal R, Keeney GA, Winterhoff B, Jones MB, Mariani A, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109(2):263–9. https://doi.org/10.1016/j.ygyno.2008.01.024.CrossRefPubMedPubMedCentral

16.

Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 2005;36(8):886–92. https://doi.org/10.1016/j.humpath.2005.05.019.CrossRefPubMed

17.

Bilodeau EA, Prasad JL, Alawi F, Seethala RR. Molecular and genetic aspects of odontogenic lesions. Head Neck Pathol. 2014;8(4):400–10. https://doi.org/10.1007/s12105-014-0588-7.CrossRefPubMedPubMedCentral

18.

Rizzitelli A, Smoll NR, Chae MP, Rozen WM, Hunter-Smith DJ. Incidence and overall survival of malignant ameloblastoma. PLoS ONE. 2015;10(2):e0117789. https://doi.org/10.1371/journal.pone.0117789.CrossRefPubMedPubMedCentral

19.

Chrcanovic BR, Gomez RS. Adenomatoid odontogenic tumor: an updated analysis of the cases reported in the literature. J Oral Pathol Med. 2019;48(1):10–6. https://doi.org/10.1111/jop.12783.CrossRefPubMed

20.

Chrcanovic BR, Brennan PA, Rahimi S, Gomez RS. Ameloblastic fibroma and ameloblastic fibrosarcoma: a systematic review. J Oral Pathol Med. 2018;47(4):315–25. https://doi.org/10.1111/jop.12622.CrossRefPubMed

21.

Bello IO, Soini Y, Slootweg PJ, Salo T. Claudins 1, 4, 5, 7 and occludin in ameloblastomas and developing human teeth. J Oral Pathol Med. 2007;36(1):48–54. https://doi.org/10.1111/j.1600-0714.2006.00497.x.CrossRefPubMed

22.

Siar CH, Abbas SA. Claudin expression and tight junction protein localization in the lining epithelium of the keratocystic odontogenic tumors, dentigerous cysts, and radicular cysts. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(5):652–9. https://doi.org/10.1016/j.oooo.2013.02.013.CrossRefPubMed

23.

Buchner A, Vered M. Ameloblastic fibroma: a stage in the development of a hamartomatous odontoma or a true neoplasm? Critical analysis of 162 previously reported cases plus 10 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(5):598–606. https://doi.org/10.1016/j.oooo.2013.06.039.CrossRefPubMed

24.

Reichart PA, Philipsen HP, Khongkhunthian P, Sciubba JJ. Immunoprofile of the adenomatoid odontogenic tumor. Oral Dis. 2017;23(6):731–6. https://doi.org/10.1111/odi.12572.CrossRefPubMed

25.

Leon JE, Mata GM, Fregnani ER, Carlos-Bregni R, de Almeida OP, Mosqueda-Taylor A, et al. Clinicopathological and immunohistochemical study of 39 cases of adenomatoid odontogenic tumour: a multicentric study. Oral Oncol. 2005;41(8):835–42. https://doi.org/10.1016/j.oraloncology.2005.04.008.CrossRefPubMed

26.

Escudero-Esparza A, Jiang WG, Martin TA. The Claudin family and its role in cancer and metastasis. Front Biosci (Landmark Ed). 2011;16:1069–83.CrossRef

27.

Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009;179(2):123–33. https://doi.org/10.1164/rccm.200803-456OC.CrossRefPubMed

28.

Higashi Y, Suzuki S, Sakaguchi T, Nakamura T, Baba S, Reinecker HC, et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res. 2007;139(1):68–76. https://doi.org/10.1016/j.jss.2006.08.038.CrossRefPubMed

29.

Pyo JS, Kim NY, Cho WJ. Prognostic role of Claudin-1 immunohistochemistry in malignant solid tumors: a meta-analysis. J Pathol Transl Med. 2019. https://doi.org/10.4132/jptm.2019.02.03.CrossRefPubMedPubMedCentral

30.

Kim NY, Pyo JS, Kang DW, Yoo SM. Loss of claudin-1 expression induces epithelial-mesenchymal transition through nuclear factor-kappaB activation in colorectal cancer. Pathol Res Pract. 2019;215(3):580–5. https://doi.org/10.1016/j.prp.2019.01.015.CrossRefPubMed

31.

Martinez-Estrada OM, Culleres A, Soriano FX, Peinado H, Bolos V, Martinez FO, et al. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J. 2006;394(Pt 2):449–57. https://doi.org/10.1042/BJ20050591.CrossRefPubMedPubMedCentral

32.

Di Cello F, Cope L, Li H, Jeschke J, Wang W, Baylin SB, et al. Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS ONE. 2013;8(7):e68630. https://doi.org/10.1371/journal.pone.0068630.CrossRefPubMedPubMedCentral

33.

Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587(9):1434–9. https://doi.org/10.1016/j.febslet.2013.03.023.CrossRefPubMed

34.

Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS, Zhou T. Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med. 2013;31(6):1375–80. https://doi.org/10.3892/ijmm.2013.1348.CrossRefPubMed

35.

Yoda S, Soejima K, Hamamoto J, Yasuda H, Nakayama S, Satomi R, et al. Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. Lung Cancer. 2014;85(3):366–72. https://doi.org/10.1016/j.lungcan.2014.06.009.CrossRefPubMed

Titel: The Significance of Relative Claudin Expression in Odontogenic Tumors
verfasst von: Ekarat Phattarataratip
Kraisorn Sappayatosok
Publikationsdatum: 31.08.2019
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 2/2020
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-019-01072-8

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Significance of Relative Claudin Expression in Odontogenic Tumors

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Follicular Lymphoma Diagnosed in Warthin Tumor: A Case Report and Review of the Literature

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): An Update

The Prevalence, Anatomic Distribution and Significance of HPV Genotypes in Head and Neck Squamous Papillomas as Detected by Real-Time PCR and Sanger Sequencing

Central Giant Cell Granuloma Treated with Intralesional Corticosteroid Injections and Bisphosphonates: A Long-Term Follow-Up Case Study

Giant Cell Tumour of Temporal Bone and Infratemporal Fossa: A Rare Case

Sporadic Neurofibroma of the Tongue Unassociated with Neurofibromatosis Type I: A Clinicopathologic Study of Ten Cases

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien